General Information of Drug (ID: DMJIH83)

Drug Name
XmAb20717 Drug Info
Synonyms XmAb717
Indication
Disease Entry ICD 11 Status REF
Advanced malignancy 2A00-2F9Z Phase 1 [1]
Breast cancer 2C60-2C65 Phase 1 [2]
Melanoma 2C30 Phase 1 [2]
Solid tumour/cancer 2A00-2F9Z Phase 1 [1]
Cross-matching ID
TTD Drug ID
DMJIH83

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Ipilimumab DMJTIYK Melanoma 2C30 Approved [4]
Tremelimumab DMOQ9H1 Hepatocellular carcinoma 2C12.02 Approved [5]
KN046 DMSDBPG Non-small-cell lung cancer 2C25.Y Phase 3 [6]
AK04 DMU7K86 Actinic keratosis EK90.0 Phase 3 [7]
AK104 DMXJ8Z4 Cervical cancer 2C77.0 Phase 2 [8]
Lorigerlimab DM2E8Z5 Prostate cancer 2C82.0 Phase 2 [9]
Vudalimab DMSEEI0 Prostate cancer 2C82.0 Phase 2 [10]
AGEN1884 DMAP5B4 Cervical cancer 2C77.0 Phase 1/2 [11]
BMS-986288 DMM10J4 Solid tumour/cancer 2A00-2F9Z Phase 1/2 [12]
MK-1308 DM25QKC Solid tumour/cancer 2A00-2F9Z Phase 1/2 [13]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Nivolumab DMAB9QE Melanoma 2C30 Approved [14]
Tislelizumab DMGVUO5 Hodgkin lymphoma 2B30 Approved [15]
MK-3475 DMBYNW0 Melanoma 2C30 Approved [14]
Pembrolizumab DMFQEA6 Melanoma 2C30 Approved [1]
Cemiplimab DMKMJHE Cutaneous squamous cell carcinoma 2C30 Approved [16]
Retifanlimab DMRKTCP Neuroendocrine cancer 2B72.1 Approved [11]
Sintilimab DMGWR0C Hodgkin lymphoma 2B30 Approved [17]
Dostarlimab DM78NWP Endometrial cancer 2C76 Approved [18]
Toripalimab DMSGA6Z Demodex blepharitis 1G07 Approved in China [19]
PDR001 DM53J6B Melanoma 2C30 Phase 3 [20]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Cytotoxic T-lymphocyte protein 4 (CTLA-4) TTI2S1D CTLA4_HUMAN Not Available [3]
Programmed cell death protein 1 (PD-1) TTNBFWK PDCD1_HUMAN Not Available [3]

References

1 Development of Inhibitors of the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Signaling Pathway.J Med Chem. 2019 Feb 28;62(4):1715-1730.
2 ClinicalTrials.gov (NCT03517488) A Study of XmAb20717 in Subjects With Selected Advanced Solid Tumors (DUET-2). U.S. National Institutes of Health.
3 Clinical pipeline report, company report or official report of Xencor.
4 Mullard A: 2010 FDA drug approvals. Nat Rev Drug Discov. 2011 Feb;10(2):82-5.
5 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2743).
6 Clinical pipeline report, company report or official report of Alphamab Oncology.
7 A multicenter, open-label phase Ib/II study of cadonilimab (anti PD-1 and CTLA-4 bispecific antibody) monotherapy in previously treated advanced non-small-cell lung cancer (AK104-202 study). Lung Cancer. 2023 Oct;184:107355.
8 Clinical pipeline report, company report or official report of Akeso Biopharma.
9 Clinical pipeline report, company report or official report of MacroGenics
10 Clinical pipeline report, company report or official report of Xencor
11 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
12 Clinical pipeline report, company report or official report of CytomX Therapeutics.
13 Safety and efficacy of quavonlimab, a novel anti-CTLA-4 antibody (MK-1308), in combination with pembrolizumab in first-line advanced non-small-cell lung cancer. Ann Oncol. 2021 Mar;32(3):395-403.
14 2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81.
15 Tislelizumab: an investigational anti-PD-1 antibody for the treatment of advanced non-small cell lung cancer (NSCLC). Expert Opin Investig Drugs. 2020 Dec;29(12):1355-1364.
16 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89.
17 Sintilimab: First Global Approval. Drugs. 2019 Feb;79(3):341-346.
18 Dostarlimab in the treatment of recurrent or primary advanced endometrial cancer. Future Oncol. 2021 Mar;17(8):877-892.
19 Toripalimab: the First Domestic Anti-Tumor PD-1 Antibody in China. Front Immunol. 2022 Jan 12;12:730666.
20 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)